Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Mult Scler (Foster City). 2014 Dec 11;2(1):1000131. doi: 10.4172/2376-0389.1000131

Table 2.

Summary of In vivo studies.

Group Dosea Disease
incidenceb 		Mean
maximal
score ± SEM
In vivo Study I: Preventive Treatment
PBS 100 µl/mouse on days 4, 7, and 10 100% 3.50 ± 0.43
PLP 100 nmol/mouse on days 4, 7, and 10 100% 2.60 ± 0.44
B7AP 100 nmol/mouse on days 4, 7, and 10 83% 1.50 ± 0.55
PLP + B7AP 100 nmol/mouse on days 4, 7, and 10 100% 1.08 ± 0.33
PLP-B7AP 100 nmol/mouse on days 4, 7, and 10 0% 0.00 ± 0.00
In vivo Study II: Potency and Dose Dependency
PBS 100 µl/mouse on days 4, 7, and 10 100% 2.92 ± 0.55
PLP-B7AP 100 nmol/mouse on day 4 100% 1.20 ± 0.20
PLP-B7AP 50 nmol/mouse on days 4, 7, and 10 17% 0.33 ± 0.33
PLP-BPI 50 nmol/mouse on days 4, 7, and 10 17% 0.30 ± 0.20
In vivo Study III: Vaccination Treatment
PBS 100 µl/mouse on days –11, –8, and –5 100% 2.56 ± 0.88
PLP-B7AP 100 nmol/mouse on days –11, −8, and −5 0% 0.00 ± 0.00
a

All injections were administered subcutaneously.

b

Incidence of disease was defined as a disease score of 1 or higher.